(Q35168565)

6 August 2017

1 reference

title

Therapy of cutaneous leishmaniasis (English)

1 reference

6 August 2017

Samuel A Lee

1

1 reference

6 August 2017

Rodrigo Hasbun

series ordinal

2

1 reference

6 August 2017

publication date

1 June 2003

1 reference

International Journal of Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

7

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

86-93

1 reference

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

American cutaneous leishmaniasis associated with HIV infection: report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia).

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Comparison of PCR results using scrape/exudate, syringe-sucked fluid and biopsy samples for diagnosis of cutaneous leishmaniasis in Ecuador

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Comparative assessment of the efficacy and toxicity of N-methyl-glucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Studies on the leishmaniases in the Sudan. 2. Clinical and parasitological studies on cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of cutaneous leishmaniasis with infrared heat

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cryosurgery in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cryotherapy in acute cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cryosurgery in old world cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Nitric oxide and macrophage function

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of cutaneous leishmaniasis with nitric-oxide donor

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A topical nitric oxide-generating therapy for cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil--an area of Leishmania (V.) braziliensis transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of leishmaniasis nodosa (oriental sore) with intralesionally injected emetine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Dapsone in the treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Efficacy of rifampicin and isoniazid in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Allopurinol in the Treatment of American Cutaneous Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Allopurinol in the treatment of American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of recurrent cutaneous Leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Ketoconazole in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Failure of ketoconazole treatment in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cutaneous leishmaniasis. Treatment with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cutaneous leishmaniasis in India. Clinical experience with itraconazole (R51 211 Janssen).

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of cutaneous leishmaniasis with oral itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Remission of localized cutaneous leishmaniasis in a HIV-positive patient using systemic terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990002-6

7 January 2021

10.1016/S1201-9712(03)90002-6

Identifiers

DOI

1 reference

6 August 2017

1 reference